Albireo to participate in upcoming investor conferences

Boston, sept. 01, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:

ALBO Ratings Summary

ALBO Quant Ranking